BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-230@pharmaconomics
DTSTAMP:20260707T005011Z
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261027
SUMMARY:IONS PDUFA — bepirovirsen
DESCRIPTION:The FDA's approval decision on bepirovirsen for chronic hepatitis B is due Oct 26\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/ef20071749_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/230
URL:https://www.pharmaconomics.com/e/230
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IONS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR